-
Qualigen closes $41 million PIPE led by Faraday Future for crypto pivot
-
Faraday Future completes $41 million investment in Qualigen Therapeutics
-
Qualigen Therapeutics regains NASDAQ compliance with $4.5 million funding
-
Qualigen Therapeutics raises $4.5 million in private placement
-
Qualigen receives patents for QN-302 drug in 25 countries
-
Qualigen Therapeutics (QLGN) receives Nasdaq deficiency notice after delayed 10-Q
-
Qualigen Therapeutics (QLGN) enters non-binding MOU to acquire Marizyme
-
Qualigen Therapeutics (QLGN) Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
-
Qualigen Therapeutics (QLGN) Announces $4.5M Convertible Preferred Shares Offering
-
Qualigen Therapeutics (QLGN) Files for 14M Share and Warrant Offering
-
Qualigen Therapeutics (QLGN) Announces management changes
-
Qualigen Therapeutics (QLGN) Received Extension from Nasdaq Hearings Panel
-
Qualigen Therapeutics (QLGN) Prices 14.72M Share Offering at $0.13/sh

